Post
Meitheal partners with Chinese company for US licencing of insulin biosimilars
Meitheal Pharmaceuticals has signed an exclusive licensing agreement with the China-based Tonghua Dongbao Pharmaceutical to commercialise three insulin biosimilars in …
Evaxion partners with Afrigen Biologics to develop mRNA gonorrhea vaccine
The Danish artificial intelligence (AI) biotech Evaxion has announced plans to develop an mRNA vaccine against gonorrhea in partnership with …
CymaBay maps out regulatory filing for primary biliary cholangitis drug seladelpar
CymaBay Therapeutics could file for a regulatory approval of its primary biliary cholangitis drug seladelpar with the US Food and …
GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with anaemia
On 15 September 2023, the US Food and Drug Administration (FDA) approved GlaxoSmithKline’s (GSK’s) Janus kinase (JAK) inhibitor, Ojjaara (momelotinib), …
Kezar and Everest enter lupus nephritis therapy development deal
Kezar Life Sciences and Everest Medicines have signed a partnership and licence agreement for the development and commercialisation of zetomipzomib for lupus …
Meitheal partners with Chinese company for US licencing of insulin biosimilars
Meitheal Pharmaceuticals has signed an exclusive licensing agreement with the China-based Tonghua Dongbao Pharmaceutical to commercialise three insulin biosimilars in …
Evaxion partners with Afrigen Biologics to develop mRNA gonorrhea vaccine
The Danish artificial intelligence (AI) biotech Evaxion has announced plans to develop an mRNA vaccine against gonorrhea in partnership with …
CymaBay maps out regulatory filing for primary biliary cholangitis drug seladelpar
CymaBay Therapeutics could file for a regulatory approval of its primary biliary cholangitis drug seladelpar with the US Food and …
GSK’s Ojjaara receives FDA approval for treating myelofibrosis patients with anaemia
On 15 September 2023, the US Food and Drug Administration (FDA) approved GlaxoSmithKline’s (GSK’s) Janus kinase (JAK) inhibitor, Ojjaara (momelotinib), …
Kezar and Everest enter lupus nephritis therapy development deal
Kezar Life Sciences and Everest Medicines have signed a partnership and licence agreement for the development and commercialisation of zetomipzomib for lupus …
FDA accepts Takeda’s NDA resubmission for eosinophilic esophagitis therapy
The US Food and Drug Administration (FDA) has accepted Takeda’s new drug application (NDA) resubmission for TAK-721 (budesonide oral suspension) …
Signal: Fresh Tracks nears end of operations with plans for dissolution
Fresh Tracks Therapeutics has announced a proposed dissolution and liquidation of the company in “an orderly fashion” as stated by …
Launching pharmaceuticals in Belgium, the Netherlands, and Luxembourg: Opportunities and challenges
Positioned near the geographic centre of the EU, the Benelux region – comprising Belgium, the Netherlands and Luxembourg – plays …
EC grants approval for Menarini’s breast cancer therapy
The European Commission (EC) has granted approval for the Menarini Group’s Orserdu (elacestrant) to treat patients with estrogen receptor (ER)‑positive, HER2-negative, …
AbCellera and Regeneron expand antibody discovery collaboration
AbCellera and Regeneron have extended their current multi-target collaboration to discover therapeutic antibodies for up to eight targets selected by …